Posted on September 2, 2022
Federal officials are expected to approve emergency authorizations as soon as this week for newly-formulated COVID-19 vaccine boosters from both Moderna and Pfizer specifically redesigned to combat the Omicron BA.5 subvariant, which currently accounts for nearly 90% of newly reported cases in the United States.
Subscribe to our e-Edition and read the rest of the story. Already a subscriber? Click here to sign in.
Recent Comments